FDA Approves ADMA Biologics’ Expanded Manufacturing Process for Intravenous Immune Globulin

ADMA will now have the ability to produce Bivigam at an expanded capacity with the same manufacturing scale, while using the same equipment, release testing assays, disposables, and labor force.